Pharma's New Manufacturing Playbook for Turbulent Times

CDMO Live 2025 Highlights: How Bayer, Boehringer Ingelheim, and Leo Pharma are rebuilding manufacturing strategiesComplexity Challenge: With thousands of SKUs to manage (Bayer handles 5,000+, half outsourced), companies struggle with aging portfolios and aggressive commercial expansion.Geopolitical Reshuffling: A staggering 62% of pharma companies are restructuring their manufacturing footprints in response to global tensions.Different Resilience Approaches:- Boehringer Ingelheim (family-owned) maintains dual sourcing despite higher costs- Leo Pharma focuses on strategic partnerships for smaller-volume products- Bayer's "Project Martini" shifts from Euro-centric to regional productionAI Adoption: Still early days, but promising applications in contract management, document processing, and predictive maintenance are emerging.Sustainability Shift: While not top priority, sustainability is increasingly viewed as both an ethical necessity and long-term cost reducer.Bottom Line: The industry is moving from pure cost optimization to balancing affordability with resilience. As Blue Jet Healthcare's MD put it: "resilience is becoming as important as costs."Download the full report